Disease · MONDO_0045057
delirium
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. delirium. Diseases, record MONDO_0045057. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0045057
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs45
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DEXMEDETOMIDINE | CHEMBL778 | Small molecule | Phase 3 | ClinicalTrials.gov | 30 | 30 | 29 | Drugs and targets |
| HALOPERIDOL | CHEMBL54 | Small molecule | Phase 3 | ClinicalTrials.gov | 22 | 22 | 22 | Drugs and targets |
| PROPOFOL | CHEMBL526 | Small molecule | Phase 3 | ClinicalTrials.gov | 10 | 10 | 10 | Drugs and targets |
| MIDAZOLAM | CHEMBL655 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| OLANZAPINE | CHEMBL715 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| QUETIAPINE | CHEMBL716 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| SEVOFLURANE | CHEMBL1200694 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| CLONIDINE | CHEMBL134 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| GABAPENTIN | CHEMBL940 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| RIVASTIGMINE | CHEMBL636 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
1 to 10 of 45
See all 45 drugsTargets102
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| GABRA1 | GABA-A receptor; anion channel | 6 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2554 | Drugs and targets |
| GABRA2 | GABA-A receptor; anion channel | 6 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2555 | Drugs and targets |
| GABRA3 | GABA-A receptor; anion channel | 6 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2556 | Drugs and targets |
| GABRA4 | GABA-A receptor; anion channel | 6 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2557 | Drugs and targets |
| GABRA5 | GABA-A receptor; anion channel | 6 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2558 | Drugs and targets |
| GABRA6 | GABA-A receptor; anion channel | 6 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2559 | Drugs and targets |
| GABRB1 | GABA-A receptor; anion channel | 6 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2560 | Drugs and targets |
| GABRB2 | GABA-A receptor; anion channel | 6 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2561 | Drugs and targets |
| GABRB3 | GABA-A receptor; anion channel | 6 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2562 | Drugs and targets |
| GABRD | GABA-A receptor; anion channel | 6 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2563 | Drugs and targets |
1 to 10 of 102
See all 102 targetsTrials82
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00221338 | Clinical Trial of Gabapentin to Decrease Postoperative Delirium and Pain | Phase 3 | 750 | 2020-09-10 | Postoperative Delirium, Postoperative Pain, Opioid Use, Hospital Length of Stay | GABAPENTIN | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT01211522 | The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study | Phase 3 | 566 | 2019-08-20 | Delirium, Impaired Cognition, Long Term Psychologic Disorders | HALOPERIDOL, ZIPRASIDONE | Its record names the disease | ClinicalTrials.gov |
| NCT00842608 | Pharmacological Management of Delirium | Not applicable | 551 | 2017-03-24 | Delirium, Cognitive Impairment | HALOPERIDOL | Its record names the disease | ClinicalTrials.gov |
| NCT01739933 | The MENDS2 Study, Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients With Acute Respiratory Failure | Phase 3 | 438 | 2021-06-07 | Sepsis, Delirium, Impaired Cognition | DEXMEDETOMIDINE, PROPOFOL | Its record names the disease | ClinicalTrials.gov |
| NCT02819141 | Self-management of Sedative Therapy by Ventilated Patients | Phase 2/3 | 161 | 2025-10-02 | Critical Illness, Anxiety, Respiratory Failure | DEXMEDETOMIDINE | Its record names the disease | ClinicalTrials.gov |
| NCT05733286 | REPOSE Study: Reducing Delirium by Enhancing Postoperative Sleep With Suvorexant | Phase 2 | 142 | 2026-01-15 | Delirium in Old Age | SUVOREXANT | Its record names the disease | ClinicalTrials.gov |
| NCT02691013 | The Impact of Ramelteon on Sleep and Delirium in Patients Who Undergo Pulmonary Thromboendarterectomy (PTE) Surgery | Not applicable | 120 | 2019-09-20 | Delirium, Sleep Deprivation | RAMELTEON | Its record names the disease | ClinicalTrials.gov |
| NCT04578886 | The Effect of Guanfacine on Delirium in Critically Ill Patients | Phase 3 | 100 | 2024-04-17 | Delirium | GUANFACINE | Its record names the disease | ClinicalTrials.gov |
| NCT01949662 | Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer | Phase 2 | 93 | 2020-10-30 | Advanced Cancers | HALOPERIDOL, LORAZEPAM | Its record names the disease | ClinicalTrials.gov |
| NCT03021486 | Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer | Phase 2/3 | 70 | 2022-09-01 | Advanced Malignant Neoplasm, Delirium, Locally Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm | CHLORPROMAZINE, HALOPERIDOL | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 82
See all 82 trialsComparisons in its trials35
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Gabapentin vs Placebo: Incidence of Postoperative Delirium by Study Group | 84 of 350 | 72 of 347 | 697 | NCT00221338 | Trial comparisons |
| Gabapentin vs Placebo: deaths from any cause | 0 of 350 | 1 of 347 | 697 | NCT00221338 | Trial comparisons |
| Gabapentin vs Placebo: serious adverse events | 31 of 350 | 44 of 347 | 697 | NCT00221338 | Trial comparisons |
| Dexmedetomidine vs Propofol: Death at 90 Days | 81 of 214 | 82 of 208 | 422 | NCT01739933 | Trial comparisons |
| Dexmedetomidine vs Propofol: deaths from any cause | 89 of 214 | 86 of 208 | 422 | NCT01739933 | Trial comparisons |
| Dexmedetomidine vs Propofol: serious adverse events | 0 of 214 | 0 of 208 | 422 | NCT01739933 | Trial comparisons |
| Dexmedetomidine vs Control: deaths from any cause | 0 of 80 | 1 of 81 | 161 | NCT02819141 | Trial comparisons |
| Dexmedetomidine vs Control: serious adverse events | 12 of 80 | 5 of 81 | 161 | NCT02819141 | Trial comparisons |
| Suvorexant Arm vs Placebo Arm: deaths from any cause | 1 of 66 | 0 of 57 | 123 | NCT05733286 | Trial comparisons |
| Suvorexant Arm vs Placebo Arm: serious adverse events | 9 of 66 | 9 of 57 | 123 | NCT05733286 | Trial comparisons |
1 to 10 of 35
See all 35 comparisons in its trialsPapers from its trials59
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0045057
GET https://conductscience.org/api/diseases/v1/MONDO_0045057/drugs?page=2